It's been a long time coming for both natural gas and solar as viable sources of energy in the United States. Both have been struggling with a lack of consumer and industrial buy-in, but both could be right around the corner. Is either one standing out at the moment?
The debate is on
In the following video, Motley Fool analysts Joel South and Taylor Muckerman each weigh in on how natural gas and solar have been performing lately and which companies are taking the lead. Both options have made progress recently, with Clean Energy Fuels (NASDAQ: CLNE ) building out its "America's Natural Gas Highway" initiative and SunPower (NASDAQ: SPWR ) producing more efficient solar panels.
Has Clean Energy Fuels solved the "chicken-or-the-egg" debate?
The movement toward alternative energy is gaining momentum. One potential opportunity in this field is Clean Energy Fuels, which focuses its natural gas efforts primarily on trucking and fleets. It's poised to make a big impact on an essential industry. Learn everything you need to know about Clean Energy Fuels in The Motley Fool's premium research report on the company. Just click here now to claim your copy today.
10 Best Oil Stocks For 2015: First Security Group Inc.(FSGI)
First Security Group, Inc. operates as the holding company for FSGBank that provides banking and financial products and services to various communities in eastern and middle Tennessee and northern Georgia. The company offers various deposit services, such as checking, savings, and money market accounts, as well as certificates of deposit. It offers commercial loans, including loans to smaller business ventures, credit lines for working capital, short-term seasonal or inventory financing, and letters of credit; real estate?construction and development loans to residential and commercial contractors and developers; and consumer loans to individuals for personal, family, and household purposes, including secured and unsecured installment and term loans. The company also offers commercial mortgage loans to finance the purchase of real property; commercial leasing for new and used equipment, fixtures, and furnishings to owner-managed businesses; and leasing for forklifts, heavy equipment, and other machinery to owner-managed businesses primarily in the trucking and construction industries. It also provides trust and investment management, mortgage banking, financial planning, and electronic banking services, such as Internet banking, online bill payment, cash management, ACH originations, wire transfers, direct deposit, traveler?s checks, safe deposit boxes, United States savings bonds, and remote deposit capture, as well as equipment leasing. The company operates 38 full-service banking offices and 1 loan and lease production office. Its market areas include in Bradley, Hamilton, Jackson, Jefferson, Knox, Loudon, McMinn, Monroe, Putnam, and Union counties, Tennessee; and Catoosa and Whitfield counties, Georgia. First Security Group was founded in 1974 and is headquartered in Chattanooga, Tennessee.
Advisors' Opinion:- [By Ning Jia]
The case for First Security Group (FSGI) is interesting. It is bank holding company that is obscure, cheap and unloved. As the company completed the recapitalization earlier this year, I think the market has been under-appreciating its potential to return to growth and profitability as a result of the much-needed recapitalization.
- [By Roberto Pedone]
First Security Group (FSGI) operates as the holding company for FSGBank, which provides banking products and services to various communities in Tennessee and Georgia. This stock closed up 6.5% to $2.29 in Tuesday's trading session.
Tuesday's Range: $2.16-$2.30
52-Week Range: $1.30-$7.45
Tuesday's Volume: 80,000
Three-Month Average Volume: 509,606From a technical perspective, FSGI ripped higher here right above some near-term support levels at $2.14 to $2.12 with lighter-than-average volume. This move is quickly pushing shares of FSGI within range of triggering a major breakout trade. That trade will hit if FSGI manages to take out some near-term overhead resistance levels at $2.38 to $2.52 and then once it clears its 200-day moving average at $2.80 with high volume.
Traders should now look for long-biased trades in FSGI as long as it's trending above some key support levels at $2.14 to $2.12 and then once it sustains a move or close above those breakout levels with volume that hits near or above 509,606 shares. If that breakout triggers soon, then FSGI will set up to re-fill some of its previous gap down zone from June that started at $5.08.
10 Best Performing Stocks To Invest In Right Now: Alexion Pharmaceuticals Inc.(ALXN)
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products for treating patients with severe and life-threatening disease states in the United States, Europe, Latin America, Japan, and the Asia Pacific. It focuses on developing products for the treatment of diseases in the areas of hematology, nephrology, neurology, ophthalmology, and cancer. The company develops and commercializes Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder. It also conducts various Phase II clinical trail programs on Soliris for its usage for the treatment of cold agglutinin disease; atypical hemolytic uremic syndrome; presensitized renal transplant; kidney transplant for catastrophic antiphospholipid syndrome; ABO incompatible renal transplant; dense deposit disease; myasthenia gravis; neuromyelitis optica; and dry a ge-related macular degeneration. In addition, the company conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry; and Phase I clinical trails on Samalizumab for the treatment of oncology diseases, such as chronic lymphocytic leukemia and multiple myeloma. Alexion Pharmaceuticals, Inc. serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company was founded in 1992 and is headquartered in Cheshire, Connecticut.
Advisors' Opinion:- [By Ben Levisohn]
That would be Amgen (AMGN), which fell 1.4% today,� Biogen Idec (BIIB), which dropped 5.1%, Celgene�(CELG), which declined 2.1%, Gilead Sciences (GILD), which dropped 4%, Regeneron Pharmaceuticals (REGN), which fell 3.8%, and Alexion Pharmaceuticals (ALXN), which finished off 1.1%.
10 Best Performing Stocks To Invest In Right Now: Courier Corporation(CRRC)
Courier Corporation, together with its subsidiaries, engages in printing, publishing, and selling books. It operates in two segments, Book Manufacturing and Specialty Book Publishing. The Book Manufacturing segment produces hard and softcover books, as well as offers related services involved in managing the process of creating and distributing these products for publishers, religious organizations, and other information providers. The Specialty Book Publishing segment publishes books in approximately 30 specialty categories, including fine and commercial arts, children?s books, crafts, music scores, graphic design, mathematics, physics and other areas of science, puzzles, games, social science, stationery items, and classics of literature for juvenile and adult markets in the United States. This segment also publishes approximately 900 test preparation and study guide titles for teachers and other consumers; and 130 titles comprising books on home decoration, design, and improvement, as well as gardening and landscaping for the home and garden retail book market. This segment sells its products through its specialty catalogs and through the Internet at doverpublications.com, REA.com, and creativehomeowner.com; and maintains DoverDirect.com, which is a business-to-business site for its retailers and distributors. This segment also sells its products through bookstore chains, independent booksellers, mass merchandisers, children?s stores, craft stores, gift shops, college bookstores, teachers? supply stores, and home and garden centers, as well as through a range of distributors in the United States and internationally. The company was founded in 1824 and is headquartered in North Chelmsford, Massachusetts.
Advisors' Opinion:- [By Tim Melvin]
CPLP reaffirmed its commitment to paying the dividend of 93 cents per share going forward, and at that level the shares yield 8.65%. The F score is 7, so conditions are improving for the company and the stock is actually trading at a more than a 35% discount to its Graham number valuation of $16.
Courier Corporation (CRRC)Courier Corporation (CRRC) publishes and prints books that are distributed through a variety of retail outlets. It publishes books on things like landscaping, gardening and home improvement that are found in many of the leading home and garden stores. Courier also publishes more than 700 test preparation and study guides for teachers and students as well books for religious institutions.
10 Best Performing Stocks To Invest In Right Now: Carmike Cinemas Inc.(CKEC)
Carmike Cinemas, Inc. operates as a digital cinema and 3D motion picture exhibitor in the United States. It operates theatres that show films on a first-run basis; and discount theatres. The company serves small to mid-size non-urban markets. As of December 31, 2011, it owned, operated, or had an interest in 237 theatres with 2,254 screens located in 35 states. The company was founded in 1982 and is headquartered in Columbus, Georgia.
Advisors' Opinion:- [By Chad Fraser] Christmas is a time for good cheer, reflection and spending time with friends and family. Here are four stocks that reflect the season, ranging from Christmas tree providers to toymakers and beyond:
Weyerhaeuser (NYSE: WY): Some little-known Christmas tree facts: there are 25 million to 30 million sold in the U.S. every year, with about 350 million currently growing in the country. It takes an average of seven years to grow a Christmas tree to its proper height.
Most Christmas tree farms are privately owned, but they need to get good seedlings from somewhere, so many turn to timber company Weyerhaeuser, which grows the most popular species—including balsam fir, Douglas fir, Scotch pine and white pine.
Weyerhaeuser controls about 6 million acres of timberland, with about a third of that in the Pacific Northwest, which is America’s most prolific lumber-producing region thanks to its cool, damp climate and considerable rainfall.
“The fact that it’s the largest timber producer in the Pacific Northwest makes Weyerhaeuser extremely attractive, because the company’s location gives it easy export access to China,” wrote Investing Daily analyst Benjamin Shepherd in a December 13 article. “This location also leaves it well-placed to pick up the supply slack created by lower production caps in Canada, which is typically a key Chinese supplier.”
Mattel (NYSE: MAT) is proving that the most traditional toys you can think of—dolls—still have a place under the tree, even in the digital age. As we reported on October 16, Mattel’s doll lineup was the main reason why its third-quarter earnings surged past Wall Street estimates.
The company’s strength is centered on its ability to come up with popular new dolls while reimagining the tried-and-true. Right now, its Monster High franchise, which it rolled out in 2010, is stealing the show: the brand’s p - [By Michael Lewis]
With the $175 million Iron Man 3 opening weekend just passed, it may be hard to remember that the first quarter of this year was a rough one for the movie business. Weak theater attendance and a lack of big-draw films made it an ugly quarter for studios and theaters alike. Carmike Cinemas (NASDAQ: CKEC ) was no exception. Especially frustrating was that this year's weak quarter follows Carmike's record first quarter from 2012. Long term, though, this is a growing company that is well managed and holds a lucrative niche spot in the competitive, low-margin theater business. Here's what you need to know about Carmike Cinemas.
- [By John Udovich]
The shares of small cap IMAX Corporation (NYSE: IMAX) have slipped more than 10% this week on growth concerns - meaning it might be a good idea to take a closer look at the stock plus its performance�verses other cinema stocks like Carmike Cinemas, Inc (NASDAQ: CKEC), Cinemark Holdings, Inc (NYSE: CNK) and Regal Entertainment Group (NYSE: RGC) along with the PowerShares Dynamic Leisure & Entertainment ETF�(NYSEARCA: PEJ).
10 Best Performing Stocks To Invest In Right Now: Nomura Holdings Inc (NRSCF)
Nomura Holdings, Inc. is engaged in the investment and financial services business with a focus on securities business. The Company's business operations include financing, asset management, securities trading and brokerage, underwriting and sale of securities, private placement of securities, own funds Investment activities, and other securities and finance-related activities. As of March 31, 2013, the Company owned 738 consolidated subsidiaries. Advisors' Opinion:- [By Daniel Inman]
Securities firms were in focus in Tokyo after Nomura Holdings (JP:8604) � (NRSCF) �and Daiwa Securities Group (JP:8601) � (DSECF) �reported second-quarter earnings. Daiwa rose 3.4% after reporting its net profit slid 38% on the previous quarter on decreased equity trading, which was above consensus expectations. Analysts say it already is factored into the price.
- [By WWW.MARKETWATCH.COM]
LOS ANGELES (MarketWatch) -- Japanese stocks have ended with losses in every session this week, and sure enough, the Nikkei Average (JP:NIK) was down 0.6% in early Friday trade, though off an opening 0.8% defecit, while the Topix carried a 0.7% loss. Overnight losses for the U.S. and further strength in the yen (with the dollar falling to 楼101.28 from 楼101.56 a day earlier) helped drag the market lower, as did results from Fast Retailing Co. (JP:9983) (FRCOF) , the shares of which hold the heaviest weighting on Nikkei Average. Fast Retailing said that while its Uniqlo brand was doing great business, weakness for its J Brand luxury demin label helped send September-May profit down 4% and prompted another cut to Fast's full-year outlook. Consequently, its shares traded 0.7% lower, though rivals Takashimaya Co. (JP:8233) and J. Front Retailing Co. (JP:3086) (JFROF) also saw losses of 0.6% and 0.5%, respectively. Among other decliners, Sony Corp. (JP:6758) (SNE) lost 0.7%, Toshiba Corp. (JP:6502) (TOSYY) fell 2.1%, Kawasaki Heavy Industries Ltd. (JP:7012) (KWHIY) fell 1.5%, Toyota Motor Corp. (JP:7203) (TM) and Nissan Motor Co. (JP:7201)
10 Best Performing Stocks To Invest In Right Now: Kinross Gold Corporation(KGC)
Kinross Gold Corporation, together with its subsidiaries, engages in mining and processing gold ores. It also involves in the exploration and acquisition of gold bearing properties. The company?s gold production and exploration activities are carried out principally in the Americas, Africa, and the Russian Federation. As of December 31, 2010, its proven and probable mineral reserves were 62.4 million ounces of gold, 90.9 million ounces of silver, and 1.4 billion pounds of copper. The company was founded in 1972 and is based in Toronto, Canada.
Advisors' Opinion:- [By Ben Levisohn]
On an adjusted basis, Eldorado Gold (EGO) has the longest reserve/resource life amongst our coverage companies (39 years) with Goldcorp (GG) having the longest reserve/resource life (23 years) amongst the senior producers versus the group average of 22 years. Kinross Gold (KGC) and Iamgold (IAG) have the shortest adjusted reserve/resource lives amongst the senior and mid-tier producers (18 and 14 years respectively). On a percentage basis, the companies most affected by the adjustment are New Gold (NGD) and Iamgold which both saw reserve/resource lives fall by 47% however, we note that despite the adjustment,�New Gold still has the second longest reserve/resource life in our group (37 years). Newmont Mining was the least affected by the adjustments with reserve/resource life declining by only 12% to 22 years from 25 years.
- [By Hebba Investments]
Even with rising Q2 costs, GG still has lower true all-in costs than many of its larger competitors' Q1FY13 costs. Compared to Q1FY13 numbers of competitors such as Yamana Gold (AUY) (costs just over $1300), Kinross Gold (KGC) (costs above $1350), Silvercrest Mines (SVLC) (costs below $1100), Newmont Gold (NEM) (costs around $1300) Agnico-Eagle (AEM) (costs around $1400) and Barrick Gold (ABX) (costs around $1200).
10 Best Performing Stocks To Invest In Right Now: ChemoCentryx Inc (CCXI)
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�� wholly owned subsidiary is ChemoCentryx Limited.
The Company's drug candidate Traficet-EN (CCX282, GSK'786), is to control the inflammatory response underlying IBD by targeting the chemokine receptor known as CCR9. The Company has completed nine clinical trials with Traficet-EN in a total of 785 subjects, including five Phase I clinical trials (three in the United States and two in the United Kingdom), one thorough QT study in the United States (an assessment of cardiovascular safety which is required for regulatory approval), and three Phase II clinical trials (one in the Netherlands, the United Kingdom, and the United States, one in Finland and one (PROTECT-1) in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, South Africa, Sweden and the United Kingdom). As of December 31, 2011, the Company�� Traficet-EN drug candidate is in four pivotal Phase III clinical trials being conducted by its partner Glaxo Group Limited (GSK).
The Company's independent drug candidate CCX140, targets the chemokine receptor known as CCR2. CCX140 is a potent and selective antagonist of CCR2 that is found on subsets of monocytes and macrophages, which are cells of th! e immune system. In January 2011, the Company completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety and tolerability of CCX140 in patients with type 2 diabetes. In addition, CCX140 demonstrated biological activity through a dose-dependent decrease in fasting plasma glucose.
CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of rheumatoid arthritis (RA) patients contains high levels of activated CCR1 chemokine ligands. The Company completed two Phase I clinical trials in a total of 84 healthy subjects, conducted in Switzerland followed by a Phase I/II clinical trial in 24 patients with stable RA, conducted in Belgium and Romania, and a Phase II proof-of-concept clinical trial in 160 patients with moderate-to-severe RA, conducted in Belgium, the Czech Republic, Germany, Hungary, Poland, Romania and the Ukraine. GSK exercised its option to further develop and commercialize CCX354 in November 2011 and had an exclusive right to initiate a Phase II b clinical trial for CCX354 in RA.
CCX168 targets the chemo-attractant C5a receptor (C5aR), which binds to a biologically activated fragment of the complement protein known as C5. As of December 31, the Company completed a Phase I clinical trial for CCX168, conducted in Switzerland. The Company initiated a Phase II proof-of-concept clinical trial in AAV in the fourth quarter of 2011. Its CCX872 is an independent next generation CCR2 drug candidate for the treatment of metabolic diseases, its CCX507 is an independent drug candidate for the treatment of inflammatory bowel disease (IBD) and CCX662 is an independent drug candidate for the treatment of glioblastoma multiforme (GBM).
The Company competes with Abbott Laboratories, Amgen Inc, AstraZeneca plc, Biogen Idec Inc, Bayer AG, Elan Corporation plc, Glaxo Group Limited, Merck & Co Inc, Merck Serono, Takeda Pharmaceutical Co Ltd, Novartis AG! , Pfizer ! Inc, Reata Pharmaceuticals, Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Incyte Corp and UCB Pharma.
Advisors' Opinion:- [By CRWE]
ChemoCentryx, Inc. (Nasdaq:CCXI), reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 7, 2012, at 9:30 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York, NY.
- [By James E. Brumley]
The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that plagued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.
No comments:
Post a Comment